Cereno Scientific planerar att initiera prekliniska sjukdomsmodellstudier med kandidaten CS585 vid antifosfolipidsyndrom, en sällsynt autoimmun sjukdom som orsakar återkommande blodproppar och allvarliga kardiovaskulära komplikationer. https://t.co/M0nKgFLINp
Cereno Scientific har ingått ett samarbete med PHA Europe & Global, en paraplyorganisation som representerar mer än 40 nationella patientföreningar. https://t.co/fUUTJePHtM
Cereno Scientific — Long-term EAP data confirms CS1’s safety
Cereno Scientific has reported encouraging initial observations from the 12-month Expanded Access Program (EAP)… @CerenoSciAB $CRNO
📖 Full analysis: https://t.co/wvLqV7xb0i
Cereno Scientific tar ett viktigt steg i utvecklingen av nästa generations behandlingar för patienter med sällsynta hjärt- och lungsjukdomar💊✨
https://t.co/xdjJbC4FwD
Ni missar väl inte dagens Market Update? 👀
Cereno Scientific, som önskats fram av programmets tittare, gästar studion och intervjuas live!
Frågor går att ställa i chatten, live 11.00 👇👇
https://t.co/P6SVlPk7wS
#Finanstwitter#PrataPengar#fintwitt
Cereno Scientific — CMD reaffirms shifting focus to clinical delivery
Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development… @CerenoSciAB $CRNO-B
📖 Full analysis: https://t.co/WjsHGq7OIz
Cereno widens clinical program as competition heats up in lung disease
https://t.co/GVlJ6pnAZL
Swedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung d...
Cereno Scientific — Entering a value inflection phase
We refresh our investment case for Cereno Scientific as the company enters a key value inflection period... #OMX $CRNO-B
📖 Read the full report here: https://t.co/6NnsuYq56q
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA #CerenoScientific, #Cereno, #CRNOB https://t.co/X4wWkIhnDa
$IonQ Expands Nordic Presence in Life Sciences Innovation
At NLS Days 2025 in Gothenburg, Lorenzo Roversi (IonQ) joined the panel “Gothenburg’s Global Entrepreneurs” alongside leaders from Cereno Scientific, LuceroBio, and OnDosis.
The discussion focused on how pioneering technologies scale globally, highlighting IonQ’s growing involvement in quantum applications for biotech and life sciences a key step in bridging quantum computing and medical innovation across Europe.
Link: https://t.co/rv9CQIaHMx
#IonQ #QuantumComputing #LifeScience #NLSDays #Biotech #Innovation #Sweden #QAlliance
Podcast: Cereno Scientific Turns To Old Drug For Rare Cardiopulmonary Diseases — Click the image below to read more! || #InVivo | Start your free trial today: https://t.co/l8WABoJGmx https://t.co/M1nFaFL9gK